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The story of drotrecogin alfa – 
evidence-based or evidence-biased?
To the Editor: In 2003, Taylor et al.1 posed the question: ‘Should 
health care money in South Africa be spent on drotrecogin alfa 
[Xigris]?’ Based on scientific and financial considerations, they 
concluded that the answer should be ‘no’. In addition to raising 
questions concerning cost-effectiveness within the South African 
context, the authors highlighted concerns of the validity of the 
evidence. Methodological flaws within the PROWESS study2 were 
noted: the protocol was amended mid-trial, and the study’s beneficial 
findings were only identified following this amendment, questioning 
the extent to which they were influenced.
Macias and Levy3 – both employees of Eli Lilly and Company (the 
manufacturers of Xigris) – refuted the assertions of Taylor et al. by 
implying that the granting of marketing authorisation by 40 countries 
defied the ‘lone voice in the wilderness’. 
On 25 October 2011, both the US Food and Drug Administration 
(FDA)4 and European Medicines Agency (EMA)5 announced their 
intentions to withdraw marketing rights for Xigris in the USA and 
Europe. This course of action followed the findings of the placebo-
controlled PROWESS-SHOCK study: drotrecogin alfa did not elicit 
a statistically significant reduction in 28-day all-cause mortality, 
and also failed – in its secondary endpoint – to reduce mortality in 
patients with severe protein C deficiency.5
Ironically, we echo the concluding remarks of Macias and Levy:3 
‘In evaluating new and novel therapies, health care providers and 
health care payers should analyse objectively and fairly all available 
data, be transparent in their decision-making process, and be 
accountable to patients and their families for their recommendations 
to accept or reject novel life-saving therapy’. We suggest that this same 
level of accountability and transparency should be extended to the 
manufacturing fraternity, ensuring that patients and their families are 
not offered false hope in the interests of profit generation.
This situation presents valuable learning opportunities for the 
South African healthcare community: (i) a more critical approach 
is required towards the analysis of clinical literature presented in 
support of new chemical entities; especially those that offer marginal 
benefit, are potentially unsafe, and come at a high cost; (ii) this critical 
mindset is even more pressing in a resource-poor environment, 
such as South Africa; and (iii) South Africa can ill afford 8 years of 
wasteful spending when legitimate concerns regarding safety, efficacy 
and affordability have been raised in the literature. These warnings 
need to be heeded earlier to ensure that equitable access is directed 
towards, rather than away from, interventions of clear clinical benefit.
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PSA screening reduces prostate cancer 
mortality
To the Editor: I refer to the editorial by D G Burns entitled ‘Prostate 
cancer – is screening the solution?’¹ Although a number of relevant 
points are raised in his editorial, it is blatantly inaccurate to report 
that the European Randomised Study of Screening for Prostate 
Cancer (ERSPC) showed ‘little or no effect on mortality from the 
disease over a prolonged follow-up period’. At a median follow-up 
of 9 years there was a 20% relative reduction in rate of death from 
prostate cancer among men between the ages of 55 and 69 years.² 
In a subsequent publication, which corrected for non-attendance in 
men randomised to the screening arm and contamination (having a 
prostate-specific antigen test) in men randomised to the control arm, 
the risk reduction was even greater. In the men actually screened, 
the risk of dying of prostate cancer was reduced by up to 31%.³ 
Over-diagnosis and the large numbers needed to screen and treat to 
prevent one death are a concern. We should not be asking whether 
screening improves survival as there is good evidence to support that 
it does. We should rather ask whether we can afford it and whether we 
are prepared to accept the morbidity associated with treating a large 
number of patients who may not benefit from treatment.
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Dr Burns replies: Lisa Kaestner is correct in pointing out that in the 
ERSPC there was a 20% relative reduction in mortality from prostate 
cancer, but the other landmark USA-based Prostate, Lung, Colorectal 
and Ovarian (PLCO) Cancer Screening Trial failed to show a 
similar mortality benefit over a 7 - 10-year period.1,2 These were 
both complex trials, and it is possible that the failure to confirm the 
findings of the ERSPC study may have been influenced by the lower 
number of men entered into the PLCO study (76 693 v. 182 000), and 
failure to correct for ‘contaminators’ in the control group in the USA 
study. However, it also confirms that screening of very large numbers 
of subjects was required to demonstrate any statistical mortality 
benefit, with substantial overtreatment and a very small proportion 
of men ultimately benefiting from such interventions. Based on 
these studies, it indeed seems appropriate to question whether this 
margin of clinical benefit is worth the financial and morbidity costs 
of population-based screening. In fact, recently the US Preventive 
Services Task Force is reported to have posted a preliminary draft 
recommendation against PSA-based screening for prostatic cancer 
in all age groups, based on the publication of the above two trials.3
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